P2RY12 and metabolic syndrome: In contrast, the patients with Malignancy group had lower body weight, BMI, ACS, systolic and diastolic blood pressure at administration, dyslipidemia, culprit vessel of right coronary artery, hemoglobin (Hgb), platelet count, P2Y12 inhibitor, DAPT, angiotensin converting enzyme inhibitor /angiotensin receptor blocker, β-blocker, statin, Ezetimibe, and proton pump inhibitor.